¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"pathologic cell"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
17
¿µ¹®
ÇѱÛ
Leydig cell tumor
¶óÀ̵ðÈ÷¼¼Æ÷Á¾¾ç
light cell
¹àÀº¼¼Æ÷
lipoid cell
ÁöÁú¼¼Æ÷
luteal cell
Ȳ(»ö)ü¼¼Æ÷
lymphoid cell
¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ¸ð¾ç¼¼Æ÷
lymphokine-activated killer cell
¸²Æ÷Ä«ÀÎȰ¼º»ìÇØ¼¼Æ÷
lymphopoietic cell
¸²ÇÁ±¸Çü¼º¼¼Æ÷
lymphosarcoma cell leukemia
¸²ÇÁÀ°Á¾¼¼Æ÷¹éÇ÷º´
lacunar cell
°ø°£¼¼Æ÷
mitotic cell
À¯»çºÐ¿±â¼¼Æ÷
mitral cell
½Â¸ð¼¼Æ÷
mixed germ cell tumor
È¥ÇÕÁ¾ÀÚ¼¼Æ÷Á¾¾ç
monocyte-macrophage cell system
´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë, ´ÜÇÙ±¸´ë½Ä¼¼Æ÷°èÅë
mononuclear cell
´ÜÇÙ¼¼Æ÷, ´ÜÇÙ±¸
mossy cell
À̳¢¼¼Æ÷
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
17
¿µ¹®
ÇѱÛ
nucleated cell
À¯ÇÙ¼¼Æ÷
null cell
¹«Ç¥Áö¼¼Æ÷
nurse cell
(¢¡supporting cell) ¹öÆÀ¼¼Æ÷
oat cell carcinoma
±Í¸®¼¼Æ÷¾ÏÁ¾
osmiophilic cell
Ä£¿À½º¹Å¼¼Æ÷
oxyntic cell
(¢¡parietal cell) º®¼¼Æ÷
oxyphilic cell
È£»ê¼¼Æ÷
packed red blood cell
³óÃàÀûÇ÷±¸
parafollicular cell
¼ÒÆ÷°ç¼¼Æ÷
paralutein cell
ȲüÁÖÀ§¼¼Æ÷, ºÎȲü¼¼Æ÷
parietal cell
º®¼¼Æ÷
perivascular cell
Ç÷°üÁÖÀ§¼¼Æ÷
phagocytic cell
Æ÷½Ä¼¼Æ÷
pheochrome cell
ºÎ½Åģũ·Ò¼¼Æ÷
photoreceptor cell
(¢¡visual cell) ½Ã°¢¼¼Æ÷
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
17
¿µ¹®
ÇѱÛ
human T cell leukemia virus type I
Á¦1Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
human T cell leukemia virus type I
Á¦1Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
human T cell leukemia virus type II
Á¦2Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
human T cell leukemia virus type II
Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
human T-cell lymphotrophic virus
Àΰ£ T¼¼Æ÷ ¸²ÇÁ ¿µ¾ç¼º ¹ÙÀÌ·¯½º
human t-cell leukemia virus
ÀÎü T¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
hybrid cell
ÇÏÀ̺긮µå¼¼Æ÷
hybridoma, B cell
B¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
hybridoma, T cell
T¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
hypercomplex cell
Ãʺ¹ÇÕ¼¼Æ÷(õ±ÜÜùêá¬øà)
hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
IIÇü
hypersensitivity reactions,type iv(cell-mediated)
IVÇü
hypersensitivity, cell-mediated
¼¼Æ÷¸Å°³ °ú¹Î¹ÝÀÀ
hypersensitized cell
°ú°¨ÀÛ¼¼Æ÷.
hypoglycemia, beta cell tumor
ÀúÇ÷´ç(Áõ), º£Å¸¼¼Æ÷Á¾
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
17
¿µ¹®
ÇѱÛ
cell strain
¼¼Æ÷ÁÖ
cell strain
¼¼Æ÷ÁÖ(á¬øàñ»).
cell substitution
¼¼Æ÷ġȯ, Ç÷±¸Àç»ý(Ì´Ë´ ?Ë×).
cell substitution
¼¼Æ÷ġȯ, Ç÷±¸Àç»ý(úìϹ î¢ßæ).
cell surface characteristic
¼¼Æ÷Ç¥¸éƯ¼º
cell surface receptor
¼¼Æ÷Ç¥¸é¼ö¿ëü
cell survival curve
¼¼Æ÷»ýÁ¸°î¼±
cell transformation
¼¼Æ÷ÇüÁúÀüȯ, ¼¼Æ÷º¯Çü
cell typing
Ç÷±¸Çü°Ë»ç
cell wall
¼¼Æ÷º®
cell wall
¼¼Æ÷º®.
cell wall antigen
¼¼Æ÷º®Ç׿ø
cell wall inhibitor
¼¼Æ÷º®ÇÕ¼º¾ïÁ¦Á¦
cell wall teichoic acid
¼¼Æ÷º® ŸÀÌÄÚ»ê
cell, HeLa
HeLa¼¼Æ÷
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
17
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
17
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
17
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
17
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
17
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
17
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½